Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | SI | P14410 | 1/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15334365 | 0.86 | GAA (0.52) | MAPTL3MBTL1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL703931 | 0.86 | MAPT (0.72) | MAPTPOLBL3MBTL1TSHRKMT2A | |
| SCHEMBL4077327 | 0.85 | KMT2A (0.49) | MAPTSMN1; SMN2KMT2ACYP4Z1GAA | |
| SCHEMBL6025472 | 0.84 | ALDH1A1 (0.56) | MAPTPOLBL3MBTL1TSHRMEN1 | |
| SCHEMBL3678807 | 0.84 | CYP4F2 (0.55) | MAPTPOLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3412717 | 0.84 | MAPT (0.51) | MAPTPOLBL3MBTL1SMN1; SMN2TSHR | |
| SCHEMBL14390296 | 0.83 | CYP4Z1 (0.46) | MAPTSMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL699965 | 0.83 | KDM4E (0.50) | MAPTPOLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL21572817 | 0.83 | CYP4Z1 (0.46) | MAPTSMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL4812296 | 0.83 | KMT2A (0.48) | MAPTPOLBL3MBTL1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319703-B2 | Macrocyclic fused pyrazoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| CN-117561260-A | Heterocyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11884648-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2023016296-A1 | HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2023-02-16 | — | — | WO | disclosed |
| CN-112204036-B | Macrocyclic fused pyrazoles as MCL-1 inhibitors | 苏州亚盛药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-20220396587-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-15 | — | — | US | disclosed |
| US-20220396587-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-15 | — | — | US | disclosed |
| CN-109311822-B | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-4011876-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-114478409-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-1682554-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | Pfizer Products Incorporated (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006035310-A2 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| WO-2005044822-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| US-5929067-A | N-ACYLATING AMINE DERIVATIVE OF CAPROLACTAM COMPOUND WITH A CARBOXYLIC ACID OR DERIVATIVES TO FORM AMIDE DERIVATIVE OF CAPROLACTAM COMPOUND | NOVARTIS AG (CH) | 1999-07-27 | — | — | US | disclosed |
| EP-0810991-B1 | 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS | NOVARTIS AG (CH) | 1999-04-14 | — | — | EP | disclosed |
| EP-0810991-A1 | 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS | Novartis AG (CH) | 1997-12-10 | — | — | EP | disclosed |
| WO-1996026183-A1 | 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS | NOVARTIS AG (CH) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396587-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | MCL1, BCL2A1, BCL2L1 | MAPT 2644/4885POLB 1832/4885L3MBTL1 12/4885 |
| US-12319703-B2 | Macrocyclic fused pyrazoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | MAPT 2417/4885POLB 1583/4885L3MBTL1 7/4885 |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | CNR2, CNR1, GPR18 | MAPT 3330/4885POLB 4554/4885L3MBTL1 4397/4885 |
| US-11884648-B2 | Histone demethylase inhibitors | DOT1L, KDM1B, KDM1A | MAPT 3339/4885POLB 904/4885L3MBTL1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.